Harbin Medical University

This phase 2 trial is investigating whether adding an experimental drug called retlirafusp alfa to standard chemotherapy or to another drug called fuzuloparib can improve outcomes for people with triple-negative breast cancer (TNBC). The study includes two groups: one with early-…

This study tests whether giving two drugs (trastuzumab rezetecan and adebrelimab) before surgery can eliminate or shrink tumors in people with a specific type of muscle-invasive bladder cancer (HER2-positive). About 58 adults will receive the combination, then have their bladder …

This early-phase trial tests a combination of two drugs—aipalolitovorelizumab and fruquintinib—in 18 people with advanced colorectal cancer that has not responded to at least two prior treatments. The goal is to see if the combo can shrink tumors or slow the disease. Participants…

This early study tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab), a targeted therapy (olaparib), and chemotherapy (paclitaxel) given before surgery to 20 women with early, high-risk triple negative breast cancer that has a specific DNA repair defect …

This early-phase study will test a combination of three drugs—camrelizumab (an immunotherapy), pirfenidone (an anti-fibrotic drug), and standard chemotherapy—in 12 women with advanced triple-negative breast cancer that has already been treated with immunotherapy. The goal is to s…

This study tests a mobile app called 'Heart Voice: Starry Journey' designed to help parents and caregivers of children with autism feel more flexible and less anxious or depressed. About 52 caregivers will use the app for 6 weeks, doing interactive stories and exercises based on …